Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors
P Kongtim; K Adekola; D R Milton; R Ramlal; A Jimenez; J Chen; G Rondon; S Ahmed; P Kebriaei; O Betul; C M Hosing; U Popat; I Khouri; E Jabbour; J E Cortes; H M Kantarjian; R E Champlin; S O Ciurea
Author Information: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.